Skip to main content
SpringerLink
Log in

Prevention of bone loss in postmenopausal and senile osteoporosis with vitamin D analogues

  • Session IX: Treatment: Vitamin D Metabolites
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Caniggia A, Gennari C, Bianchi V, et al. Intestinal absorption of Ca in senile osteoporosis. Acta Med Scand 1963;173:613–7.

    Google Scholar 

  2. Gallagher JC, Riggs BL, Eisman J, et al. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients. J Clin Invest 1979;64:729–36.

    Google Scholar 

  3. Bullamore JR, Gallagher JC, Wilkinson R, et al. Effect of age on calcium absorption. Lancet 1970;2:535–7.

    Google Scholar 

  4. Alevizaki CC, Ikkos DG, Singhelakis P. Progressive decrease of true intestinal calcium absorption with age in normal man. J Nucl Med 1965;14:760–2.

    Google Scholar 

  5. Gallagher JC, Jerpbak CM, Jee WS, et al. l,25-dihydroxyvitaminD3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 1982;79:3325–9.

    Google Scholar 

  6. Ebeling PR, Sandgren ME, DiMagno EP. Relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women: evidence for age-related decrease in intestinal responsiveness. J Bone Miner Res 1990;5:S274.

    Google Scholar 

  7. Vega E, Mautalen C, Gomez H, et al. Bone mineral density in patients with cervical and trochanteric fractures of the proximal femur. Osteoporosis Int 1991;1:81–6.

    Google Scholar 

  8. Lips P, Van Ginkel FC, Jongen MJM, et al. Determinants of vitamin D status in patients with hip fracture and in elderly control subjects. Am J Clin Nutr 1987;46:1005–10.

    Google Scholar 

  9. Francis RM, Peacock M, Barkworth SA. Renal impairment and its effects on calcium metabolism in elderly women. Age Ageing 1984;13:14–20.

    Google Scholar 

  10. Stamp TCB, Round JM. Seasonal changes in human plasma levels of 25-hydroxycholecalciferol. Nature 1974;247:563–5.

    Google Scholar 

  11. Roginsky MS, Moo HF, Abesamis C. Season variations in serum 25-hydroxycholecalciferol. Lancet 1974;1:1235–6.

    Google Scholar 

  12. Aaron JE, Gallagher JC, Anderson J, et al. Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet 1974;1:229–30.

    Google Scholar 

  13. Bouillon RA, Auwerx JH, Lisens WD, et al. Vitamin D status in the elderly: seasonal subtrate deficiency causes 1,25-dihydroxy-cholecalciferol deficiency. Am J Clin Nutr 1987;45:755–63.

    Google Scholar 

  14. Egsmose C, Lund B, McNair P, et al. Low serum levels of 25-hydroxyvitamin D and 1,25-dihydroxy vitamin D in institutionalized old people: influence of solar exposure and vitamin D supplementation. Age Ageing 1987;16:35–40.

    Google Scholar 

  15. Majeska RJ, Rodan GA. The effect of 1,25-(OH)2D3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem 1982;257:3362–5.

    Google Scholar 

  16. Kurihara N, Ishizuka S, Kiyoki M, et al. Effects of 1,25-dihydroxy-vitamin D3 on osteoblastic MC3T3-E1. Endocrinology 1986;118:940–7.

    Google Scholar 

  17. McSheehy PM, Chambers TJ. 1.25-dihydroxyvitamin D3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption. J Clin Invest 1987;80:425–9.

    Google Scholar 

  18. Gallagher JC, Recker RR. A comparison of the effects of calcitriol or calcium supplements. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV, editors. Vitamin D: a chemical, biochemical and clinical update. New York: Walter de Gruyter, 1985:971–5.

    Google Scholar 

  19. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 1990;113:649–55.

    Google Scholar 

  20. Sato K, Higuchi Y, Nanjo M, et al. Non-invasive determination of bone mineral content in rat lumbar spines using dual-energy x-ray absorptiometry and bone mineral increase by ED-71 in ovariectomized and normal rat spine. J Bone Miner Res 1991;6(S1);S238.

  21. Aloia JF, Vaswani A, Yeh J, Ellis K, et al. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988;84:401–8.

    Google Scholar 

  22. Ott SM, Chestnut CH. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989;110:267–74.

    Google Scholar 

  23. Ott SM, Chestnut CH. Tolerance to doses of calcitriol is associated with improved bone density in women with postmenopausal osteoporosis. J Bone Miner Res 1990;5[Suppl 2]:S186.

    Google Scholar 

  24. Riggs BL, Seeman E, Hodgson SF, et al. The effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 1982;306:446.

    Google Scholar 

  25. Gruber HE, Ivey JL, Baylink DJ, et al. Long-term calcitriol therapy in postmenopausal osteoporosis. Metabolism 1984;33:295–303.

    Google Scholar 

  26. Gallagher JC. Long-term treatment of postmenopausal osteoporosis with 1,25-dihydroxyvitamin D3. In: Norma AW, et al. editors. 8th Workshop on vitamin D. Berlin: Walter de Gruyter, 1991.

    Google Scholar 

  27. Gallagher JC, Riggs BL. Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 1990;39:30–34.

    Google Scholar 

  28. Caniggia A, Nuti R, Loré F, et al. Pathophysiologic study of women with postmenopausal osteoporosis: physiological basis, assessment and treatment. In: DeLuca HF, Mazess R, editors. Osteoporosis, physiological basis, assessment and treatment. New York: Elsevier. 1990:201–13.

    Google Scholar 

  29. Shiraki M, Orimo H, Ito H, et al. Long-term treatment of postmenopausal osteoporosis with active vitamin D3 1α-hydroxycholecalciferol and 1,24-dihydroxycholecalciferol. Endocrinol Jpn 1985;32:305–15.

    Google Scholar 

  30. Sorenson OH, Andersen RB, Christiansen MS, et al. Treatment of senile osteoporosis with 1-dihydroxyvitamin D3. Clin Endocrinol 1977;7:169S-75.

    Google Scholar 

  31. Orimo H, Shiraki M, Hayashi R, et al. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with lα(OH)-vitamin D3. Bone Miner 1987;3:47–52.

    Google Scholar 

  32. Gallagher JC. Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. Metabolism 1990;39(4):27–9.

    Google Scholar 

  33. Tilyard MW. 1,25-dihydroxyvitamin D3 vs. calcium in the treatment of established postmenopausal osteoporosis. J Bone Miner Res 1990;5(S2):S275.

    Google Scholar 

  34. Orimo H, Shiraki M. Long-term use of 1α(OH)D3 in involutional osteoporosis. In: DeLuca HF, Mazess R, editors. Osteoporosis: physiological basis, assessment and treatment. New York: Elsevier; 1990.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Creighton University School of Medicine, Omaha, Nebraska, USA

    J. C. Gallagher

Authors
  1. J. C. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallagher, J.C. Prevention of bone loss in postmenopausal and senile osteoporosis with vitamin D analogues. Osteoporosis Int 3 (Suppl 1), 172–175 (1993). https://doi.org/10.1007/BF01621899

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01621899

Keywords

Search

Navigation